Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 300573.SZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 300573.SZ and 80,000+ other tickers.
See exactly how 300573.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 300573.SZ and 80,000+ other tickers.
Shenyang Xingqi Pharmaceutical Co., Ltd, based in Shenyang, China, specializes in the comprehensive process of creating, producing, and distributing ophthalmological products throughout the Chinese market. The company offers a diverse portfolio of eye care solutions, which includes items for corneal health, anti-bacterial applications, artificial tear substitutes, anti-inflammatory medications, surgical perfusion liquids, mydriatic agents, anti-fatigue treatments, and specific therapies for both incipient and severe dry eye conditions.
No recent news available.